Compare LCID & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | ICUI |
|---|---|---|
| Founded | 2007 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2020 | 1995 |
| Metric | LCID | ICUI |
|---|---|---|
| Price | $9.84 | $126.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $20.20 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 5.9M | 266.1K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | $595,271,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | $78.31 | N/A |
| Revenue Next Year | $101.66 | $4.46 |
| P/E Ratio | ★ N/A | $4,287.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.97 | $107.02 |
| 52 Week High | $25.22 | $160.29 |
| Indicator | LCID | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 29.24 |
| Support Level | $9.38 | $121.49 |
| Resistance Level | $10.70 | $136.39 |
| Average True Range (ATR) | 0.59 | 5.54 |
| MACD | 0.04 | -2.01 |
| Stochastic Oscillator | 33.05 | 8.59 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.